date,title,source
Oct-18-18,Rocket Pharmaceuticals Presents Updated Long-Term Phase 1/2 Clinical Data of RP-L102 in Fanconi Anemia Patients at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT),Business Wire
Oct-19-18,Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT),Business Wire
Nov-01-18,Rocket Pharmaceuticals Announces Participation at Upcoming Conferences,Business Wire
Nov-07-18,Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights,Business Wire
Nov-07-18,Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia,Business Wire
Nov-19-18,Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I),Business Wire
